Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis (SPIRIT-P1)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Eli Lilly and Company Identifier:
First received: September 25, 2012
Last updated: September 3, 2015
Last verified: September 2015
This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active psoriatic arthritis.

Condition Intervention Phase
Psoriasis, Arthritic
Drug: ixekizumab
Drug: Placebo
Drug: Adalimumab
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis

Resource links provided by NLM:

Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Efficacy of ixekizumab in participants with active psoriatic arthritis. Measure: American College of Rheumatology 20 Index (ACR20) [ Time Frame: 24 Weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Efficacy of ixekizumab in participants with active psoriatic arthritis. Measure: modified Total Sharp Score (mTSS) [ Time Frame: Baseline through 24 Weeks ] [ Designated as safety issue: No ]
  • Efficacy of ixekizumab in participants with active psoriatic arthritis. Measure: ACR20 [ Time Frame: Baseline through 24 Weeks ] [ Designated as safety issue: No ]
  • Efficacy of ixekizumab in participants with active psoriatic arthritis. Measure: Non-Arthritic Disease Assessments [ Time Frame: Baseline through 24 Weeks ] [ Designated as safety issue: No ]
  • Quality of life and outcome assessments. Measures: Patient Reported Outcomes (PRO) [ Time Frame: Baseline through 24 Weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 412
Study Start Date: December 2012
Estimated Study Completion Date: August 2017
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ixekizumab Dosing Regimen 1
Administered by 80 milligram (mg) subcutaneous (SC) injection
Drug: ixekizumab
Administered SC
Other Name: LY2439821
Experimental: ixekizumab Dosing Regimen 2
Administered by 80 mg SC injection
Drug: ixekizumab
Administered SC
Other Name: LY2439821
Placebo Comparator: Placebo
Placebo for ixekizumab and placebo for adalimumab administered by SC injection
Drug: Placebo
Administered SC
Active Comparator: Adalimumab
Administered by 40 mg SC injection
Drug: Adalimumab
Administered SC


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Presents with established diagnosis of active psoriatic arthritis for at least 6 months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria
  • Active psoriatic arthritis (PsA) defined as the presence of at least 3 tender and at least 3 swollen joints
  • Presence of active psoriatic skin lesion or a history of plaque psoriasis (Ps)
  • Men must agree to use a reliable method of birth control or remain abstinent during the study
  • Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment

Exclusion Criteria:

  • Current or prior use of biologic agents for treatment of Ps or PsA
  • Inadequate response to greater than or equal to 4 conventional disease-modifying antirheumatic drugs (DMARDs)
  • Current use of more than one conventional DMARD
  • Evidence of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA
  • Have participated in any study with interleukin 17 (IL-17) antagonists, including ixekizumab
  • Serious disorder or illness other than psoriatic arthritis
  • Serious infection within the last 3 months
  • Breastfeeding or nursing (lactating) women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01695239

  Show 116 Study Locations
Sponsors and Collaborators
Eli Lilly and Company
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

Responsible Party: Eli Lilly and Company Identifier: NCT01695239     History of Changes
Other Study ID Numbers: 13731  I1F-MC-RHAP 
Study First Received: September 25, 2012
Last Updated: September 3, 2015
Health Authority: United States: Food and Drug Administration
Belgium: Federal Agency for Medicinal Products and Health Products
Bulgaria: Bulgarian Drug Agency
Canada: Health Canada
Czech Republic: State Institute for Drug Control
Estonia: The State Agency of Medicine
France: Ministry of Health
Hungary: National Institute of Pharmacy
Ireland: Irish Medicines Board
Japan: Pharmaceuticals and Medical Devices Agency
Mexico: Ministry of Health
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Russia: Ministry of Health of the Russian Federation
Spain: Spanish Agency of Medicines
Ukraine: State Pharmacological Center - Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Arthritis, Psoriatic
Skin Diseases, Papulosquamous
Skin Diseases
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases
Joint Diseases
Antirheumatic Agents
Anti-Inflammatory Agents processed this record on October 21, 2016